CRISPR Therapeutics has quietly fired its head of R&D. Renowned chemist and beloved Caltech professor Robert Grubbs has passed away. And two Galapagos execs are flying the nest.
A report breaks down the merits and disadvantages of different types of cloud vendors to help healthcare organizations advance their healthcare digital transformation goals.
A recent market research report estimated that between 2021 and 2026, the market for virtual reality in healthcare will grow by nearly 35% annually, swelling the market to more than $40 billion.
We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round of virtual dealmaking and more.
Funding for digital health is blowing up, and the sky’s the limit for a healthcare world suddenly, and solidly, committed to tech innovations.
Here’s what we can expect to see more of next year.
Anish Sebastian Anish Sebastian co-founded Babyscripts in 2013 with the vision that internet enabled medical devices and big data would transform the delivery of pregnancy care. Since the company’s inception, they have raised over $37M. As the CEO of BabyScripts, Anish has focused his efforts on product and software development, as well as research validation …
By enhancing traditional in-person care with on-demand digital solutions, we can create a powerful new care model that maximizes clinical resources while meeting patients whenever and wherever they…
With Omicron, we not only don’t see the rise in death rates that were associated with the first waves, but we actually see a continuing decline in death rates, despite a radical increase in cases.
Robert Gabbay and Julia Hu Robert A. Gabbay, MD, PhD, FACP, is the Chief Scientific and Medical Officer for the American Diabetes Association (ADA), the global authority on diabetes. Dr. Gabbay leads the ADA’s efforts to drive discovery within the world of diabetes research, care and prevention. Previously, Dr. Gabbay served as the Chief Medical …
Robert Gabbay and Julia Hu, Author at MedCity News Read More »
Novartis is acquiring gene therapy developer Gyroscope Therapeutics and its lead program, a potential treatment for the vision loss disorder geographic atrophy. It’s the latest in a series of M&A…
